Last reviewed · How we verify
NCT05062655: ICOCON
Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge
NA trial testing Drug reconciliation in Hospitalized Patient in 130 participants. Status unknown.
8 December 2022
Quick facts
| Lead sponsor | Centre Hospitalier le Mans |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 130 |
| Start date | 3 August 2021 |
| Primary completion | 8 December 2022 |
| Estimated completion | 8 December 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Drug reconciliation
Conditions studied
- Hospitalized Patient — all drugs for Hospitalized Patient →
Sponsor
Centre Hospitalier le Mans
Who can join
Eligibility, any sex, with Hospitalized Patient. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient. Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity. The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management. This new organisation is part of the policy of continuous improvement of the quality and safety of care
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05062655
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier le Mans trials
Trials by the same sponsor.
- NCT07365644 — Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment · not yet recruiting
- NCT07301957 — Impact of Early Rupture of the Residual Membrane on Latency Before Labour Begins · NA · not yet recruiting
- NCT07458477 — Digital Audiometer vs. Conventional Audiometer (Gold Standard): Study of Tonal and Vocal Recognition Thresholds · NA · recruiting
- NCT06799806 — The Impact of the Therapeutic Virtual Reality Headset on Patient Anxiety in the Waiting Room Before Flexible Bronchoscop · NA · recruiting
- NCT05915663 — Impact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05062655 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier le Mans
- Last refreshed: 24 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05062655.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing